Hennion & Walsh Asset Management Inc. Purchases 44,287 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 34.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 171,999 shares of the technology company's stock after purchasing an additional 44,287 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.18% of Cogent Biosciences worth $1,858,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. nVerses Capital LLC purchased a new position in Cogent Biosciences during the 3rd quarter valued at $76,000. Creative Planning boosted its stake in shares of Cogent Biosciences by 29.6% during the 3rd quarter. Creative Planning now owns 14,324 shares of the technology company's stock valued at $155,000 after purchasing an additional 3,272 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Cogent Biosciences during the third quarter valued at about $351,000. Point72 Asset Management L.P. raised its stake in Cogent Biosciences by 56.8% in the second quarter. Point72 Asset Management L.P. now owns 10,470,398 shares of the technology company's stock worth $88,265,000 after buying an additional 3,794,150 shares in the last quarter. Finally, SkyView Investment Advisors LLC lifted its holdings in Cogent Biosciences by 25.0% in the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the technology company's stock worth $105,000 after buying an additional 2,500 shares during the period.

Analyst Ratings Changes

A number of analysts have recently commented on COGT shares. Wedbush restated a "neutral" rating and set a $11.00 target price (up previously from $10.00) on shares of Cogent Biosciences in a report on Tuesday, September 3rd. Robert W. Baird increased their target price on Cogent Biosciences from $8.00 to $10.00 and gave the stock a "neutral" rating in a research note on Thursday, September 5th. JPMorgan Chase & Co. lowered their price target on Cogent Biosciences from $22.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, August 7th. Needham & Company LLC reissued a "buy" rating and set a $16.00 price objective on shares of Cogent Biosciences in a research report on Thursday. Finally, HC Wainwright reduced their price objective on shares of Cogent Biosciences from $19.00 to $17.00 and set a "buy" rating for the company in a research note on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Cogent Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $14.67.

Cogent Biosciences Trading Down 0.3 %

COGT stock traded down $0.04 during trading on Friday, reaching $11.97. The stock had a trading volume of 343,650 shares, compared to its average volume of 1,427,291. The firm has a market cap of $1.14 billion, a PE ratio of -4.83 and a beta of 1.71. The stock's 50 day moving average is $10.90 and its two-hundred day moving average is $9.13. Cogent Biosciences, Inc. has a 52 week low of $3.67 and a 52 week high of $12.61.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The technology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period in the previous year, the company posted ($0.59) EPS. On average, research analysts anticipate that Cogent Biosciences, Inc. will post -2.25 EPS for the current year.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.